Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats

Hypertension

Volumn 45, Issue 6, 2005, Pages 1145-1152

  Emoto, Noriaki ^a   Raharjo, Sunu Budhi ^a   Isaka, Daiji ^a   Masuda, Shigeru ^a   Adiarto, Suko ^a   Jeng, Arco Y ^b   Yokoyama, Mitsuhiro ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Endothelin; Heart failure; Hypertension; Hypertrophy

Indexed keywords

2 (4 BIPHENYLYL) 1 (1H TETRAZOL 5 YL)ETHYLAMINOMETHYLPHOSPHONIC ACID; ATRIAL NATRIURETIC FACTOR; CGS 24592; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COMPLEMENTARY DNA; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENKEPHALINASE INHIBITOR; MESSENGER RNA; PREPROENDOTHELIN 1; TEMOCAPRIL; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DNA PROBE; ECHOCARDIOGRAPHY; ENZYME INHIBITION; GENE EXPRESSION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HEART WEIGHT; HEMODYNAMIC PARAMETERS; HISTOLOGY; HYPERTENSION; NONHUMAN; NORTHERN BLOTTING; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ASPARTIC ENDOPEPTIDASES; ATRIAL NATRIURETIC FACTOR; CARDIAC OUTPUT, LOW; CARDIOMEGALY; COLLAGEN; ECHOCARDIOGRAPHY; ENDOTHELIN-1; ENZYME INHIBITORS; FIBROSIS; HEART; MALE; METALLOENDOPEPTIDASES; MYOCARDIUM; NEPRILYSIN; NEUROTRANSMITTER AGENTS; PHENYLALANINE; PHOSPHONIC ACIDS; RATS; RATS, INBRED DAHL; RNA, MESSENGER; TETRAZOLES; THIAZEPINES;

EID: 20044384201     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000168944.29525.da     Document Type: Article

References (43)

1. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Jr., Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669-677.
2. Stewart DJ, Cernacek P, Costello KB, Rouleau JL. Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation. 1992;85:510-517.
3. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation. 1994;89:1573-1579.
4. Spieker LE, Noll G, Ruschitzka FT, Luscher TF. Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? J Am Coll Cardiol. 2001;37:1493-1505.
5. Luscher TF, Enseleit F, Pacher R, Mitrovic V, Schulze MR, Willenbrock R, Dietz R, Rousson V, Hurlimann D, Philipp S, Notier T, Noll G, Ruschitzka F. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation. 2002;106:2666-2672.
6. Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, Ruschitzka F, Luscher TF. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:347-354.
7. Kiowski W, Sutsch G, Hunziker P, Muller P, Kim J, Oechslin E, Schmitt R, Jones R, Bertel O. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 1995;346:732-736.
8. Campbell DJ. Vasopeptidase inhibition: a double-edged sword? Hypertension. 2003;41:383-389.
9. Burnett JC, Jr., Kao PC, Hu DC, Heser DW, Heublein D, Granger JP, Opgenorth TJ, Reeder GS. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science. 1986;231:1145-1147.
10. Rademaker MT, Charles CJ, Espiner EA, Nicholls MG, Richards AM, Kosoglou T. Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure. Clin Sci (Lond). 1996;91:283-291.
11. Seymour AA, Asaad MM, Lanoce VM, Fennell SA, Cheung HS, Rogers WL. Inhibition of neutral endopeptidase 3.4.24.11 in conscious dogs with pacing induced heart failure. Cardiovasc Res. 1993;27:1015-1023.
12. Elsner D, Muntze A, Kromer EP, Riegger GA. Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure. Am J Cardiol. 1992;70:494-498.
13. Northridge DB, Jardine AG. Alabaster CT, Barclay PL, Connell JM, Dargie HJ, Duly SG, Findlay IN, Lever AF, Samuels GM. Effects of UK 69 578: a novel atriopeptidase inhibitor. Lancet. 1989;2:591-593.
14. Tikkanen I, Tikkanen T, Cao Z, Allen TJ, Davis BJ, Lassila M, Casley D, Johnston CI, Burrell LM, Cooper ME. Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes. J Hypertens. 2002;20:707-714.
15. Mulder P, Barbier S, Monteil C, Jeng AY, Henry JP, Renet S, Thuillez C. Sustained improvement of cardiac function and prevention of cardiac remodeling after long-term dual ECE-NEP inhibition in rats with congestive heart failure. J Cardiovasc Pharmacol. 2004;43:489-494.
16. Bunag RD. Validation in awake rats of a tail-cuff method for measuring systolic pressure. J Appl Physiol. 1973;34:279-282.
17. Inoko M, Kihara Y, Morii I, Fujiwara H, Sasayama S. Transition from compensatory hypertrophy to dilated, failing left ventricles in Dahl salt-sensitive rats. Am J Physiol. 1994;267:H2471-H2482.
18. Toh R, Kawashima S, Kawai M, Sakoda T, Ueyama T, Satomi-Kobayashi S, Hirayama S, Yokoyama M. Transplantation of cardiotrophin-1-expressing myoblasts to the left ventricular wall alleviates the transition from compensatory hypertrophy to congestive heart failure in Dahl salt-sensitive hypertensive rats. J Am Coll Cardiol. 2004;43:2337-2347.
19. Seccia TM, Belloni AS, Kreutz R, Paul M, Nussdorfer GG, Pessina AC, Rossi GP. Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. J Am Coll Cardiol. 2003;1941:666-673.
20. Nakamura Y, Yoshiyama M, Omura T, Yoshida K, Izumi Y, Takeuchi K, Kim S, Iwao H, Yoshikawa J. Beneficial effects of combination of ACE inhibitor and angiotensin II type 1 receptor blocker on cardiac remodeling in rat myocardial infarction. Cardiovasc Res. 2003;57:48-54.
21. Aguirre JI, Morrell NW, Long L, Clift P, Upton PD, Polak JM, Wilkins MR. Vascular remodeling and ET-1 expression in rat strains with different responses to chronic hypoxia. Am J Physiol Lung Cell Mol Physiol. 2000;278:L981-L987.
22. Fraccarollo D, Bauersachs J, Kellner M, Galuppo P, Ertl G. Cardioprotection by long-term ET(A) receptor blockade and ACE inhibition in rats with congestive heart failure: mono- versus combination therapy. Cardiovasc Res. 2002;54:85-94.
23. Inoko M, Kihara Y, Sasayama S. Neurohumoral factors during transition from left ventricular hypertrophy to failure in Dahl salt-sensitive rats. Biochem Biophys Res Commun. 1995;206:814-820.
24. Iwanaga Y, Kihara Y, Inagaki K, Onozawa Y, Yoneda T, Kataoka K, Sasayama S. Differential effects of angiotensin II versus endothelin-] inhibitions in hypertrophic left ventricular myocardium during transition to heart failure. Circulation. 2001;104:606-612.
25. Maki T, Nasa Y, Yamaguchi F, Yoshida H, Mori M, Takada T, Horikawa E, Okano K, Takeo S. Long-term treatment with neutral endopeptidase inhibitor improves cardiac function and reduces natriuretic peptides in rats with chronic heart failure. Cardiovasc Res. 2001;51:608-617.
26. Newaz MA, Yousefipour Z, Hercule H, Truong L, Oyekan A. Chronic endopeptidase inhibition in DOCA-salt hypertension: mechanism of cardiovascular protection. Clin Exp Hypertens. 2003;25:335-347.
27. Park KS, Li Y, Zhang Y, Gerbes AL, Liu H, Swain MG, Lee SS. Effects of the neutral endopeptidase inhibitor thiorphan on cardiovascular and renal function in cirrhotic rats. Br J Pharmacol. 2003;139:81-88.
28. Roques BP, Noble F, Dauge V, Fournie-Zaluski MC, Beaumont A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev. 1993;45:87-146.
29. Corti R, Buraett JC Jr, Rouleau JL, Ruschitzka F, Luscher TF. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation. 2001;104:1856-1862.
30. Jeng AY. Utility of endothelin-converting enzyme inhibitors for the treatment of cardiovascular diseases. Curr Opin Investig Drugs. 2003;4:1076-1081.
31. Pelletier S, Battistini B, Jeng AY, Sirois P. Effects of dual endothelin-converting enzyme/neutral endopeptidase inhibitors, CGS 26303 and CGS 26393, on lipopolysaccharide or interleakin-1 beta-stimulated release of endothelin from guinea pig tracheal epithelial cells. J Cardiovasc Pharmacol. 1998;31:S10-S12.
32. Yanagisawa H, Yanagisawa M, Kapur RP, Richardson JA, Williams SC, Clouthier DE, de Wit D, Emoto N, Hammer RE. Dual genetic pathways of endothelin-mediated intercellular signaling revealed by targeted disruption of endothelin converting enzyme-1 gene. Development. 1998;125:825-836.
33. Yanagisawa H, Hammer RE, Richardson JA, Emoto N, Williams SC. Takeda S, Clouthier DE, Yanagisawa M. Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development. J Clin Invest. 2000;105:1373-1382.
34. Wada A, Tsutamoto T, Ohnishi M, Sawaki M, Fukai D, Maeda Y, Kinoshita M. Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure: comparison of effects with those of endothelin A receptor antagonism. Circulation. 1999;99:570-577.
35. Chatziantoniou C, Boffa JJ, Ardaillou R, Dussaule JC. Nitric oxide inhibition induces early activation of type I collagen gene in renal resistance vessels and glomeruli in transgenic mice. Role of endothelin. J Clin Invest. 1998;101:2780-2789.
36. Guarda E, Katwa LC, Myers PR, Tyagi SC, Weber KT. Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res. 1993;27:2130-2134.
37. Schwarz A, Godes M, Thone-Reineke C, Theuring F, Bauer C, Neumayer HH, Hocher B. Tissue-dependent expression of matrix proteins in human endothelin-1 transgenic mice. Clin Sci (Lond). 2002;103:395-435.
38. Ammarguellat F, Larouche I, Schiffrin EL. Myocardial fibrosis in DOCA-salt hypertensive rats: effect of endothelin ET(A) receptor antagonism. Circulation. 2001;103:319-324.
39. Pfeffer MA, Pfeffer JM, Fishbein MC, Fletcher PJ, Spadaro J, Kloner RA, Braunwald E. Myocardial infarct size and ventricular function in rats. Circ Res. 1979;44:503-512.
40. Schirger JA, Chen HH, Jougasaki M, Lisy O, Boerrigter G, Cataliotti A, Burnett JC Jr. Endothelin A receptor antagonism in experimental congestive heart failure results in augmentation of the renin-angiotensin system and sustained sodium retention. Circulation. 2004;109:249-254.
41. von Lueder TG, Kjekshus H, Edvardsen T, Oie E, Urheim S, Vinge LE, Ahmed MS, Smiseth OA, Attramadal H. Mechanisms of elevated plasma endothelin-1 in CHF: congestion increases pulmonary synthesis and secretion of endothelin-1. Cardiovasc Res. 2004;63:41-50.
42. Doi R, Masuyama T, Yamamoto K, Doi Y, Mano T, Sakata Y, Ono K, Kuzuya T, Hirota S, Koyama T, Miwa T, Hori M. Development of different phenotypes of hypertensive heart failure: systolic versus diastolic failure in Dahl salt-sensitive rats. J Hypertens. 2000;18:111-120.
43. Sakata Y, Yamamoto K, Mano T, Nishikawa N, Yoshida J, Miwa T, Hori M, Masuyama T. Temocapril prevents transition to diastolic heart failure in rats even if initiated after appearance of LV hypertrophy and diastolic dysfunction. Cardiovasc Res. 2003;57:757-765.